CSMG Technologies Forms Veterinary Division for Tissue Welding Technology

CORPUS CHRISTI, Texas--(BUSINESS WIRE)--CSMG Technologies, Inc., (OTCBB: CTGI), a technology management company, announced today the company has added a veterinary subsidiary under its tissue welding technology subsidiary Live Tissue Connect (LTC).

The new subsidiary is focused on the surgical treatment of animals using the company’s tissue welding technology. The company’s Ukrainian team has been active in applying the tissue welding treatment to horses and dogs. Two procedures of note include the successful resection and welding of a dog’s urinary bladder and successful reconnection of a dog’s carotid artery in an artery-to-artery reconnection procedure.

Donald S. Robbins, President and CEO of CSMG, said, "We believe the veterinary applications will have similar benefits and advantages in animals as in humans, such as faster healing time, less blood loss and less surgery time. The veterinary subsidiary will be separated from the Live Tissue Connect (LTC) human surgery subsidiaries as an autonomous tissue welding subsidiary that both LTC and CSMG shareholders can benefit.”

CSMG owns the technology and exclusive world rights to the live tissue bonding/welding device through Live Tissue Connect, Inc., a subsidiary corporation formed for the development and commercialization of the platform technology.

About CSMG Technologies' Tissue Welding/Bonding Technology

The LTC tissue bonding / welding device is a platform technology that bonds and reconnects living soft biological tissue through fusion without the use of foreign matter in contrast with conventional wound closing devices such as sutures, staples, sealant, or glues.

Surgeons at 27 Ukraine hospitals and clinics are using the tissue welding/bonding technology in clinical trials. They have completed more than 10,000 human surgeries using more than 80 types of open and laparoscopic surgical procedures, demonstrating the technology is universal in its ability to repair soft biological tissue. These surgeries included lung, neuro-surgery, nasal septum, intestine, stomach, skin, gall bladder, liver, spleen, blood vessels, nerves, alba linea, uterus, bladder, gynecological, fallopian tube, ovary and testicles and dura-matter. Cosmetic surgeries conducted with this technology include breast reduction, breast implants, mastopexy and abdominoplasty. The procedure involves little or no scarring, while restoring the normal function of the body organ or tissue.

The technology was invented and developed at the internationally renowned E.O. Paton Institute of Electric Welding, National Academy of Sciences of Ukraine, Kiev, Ukraine, headed by Professor B.E. Paton. U.S., Australian, Canadian, Ukraine and European Union patents have been issued, and additional U.S. and foreign patents are pending, all owned by LTC.

About CSMG Technologies, Inc.

CSMG Technologies (OTC BB: CTGI) is a technology management company that finances, owns, develops, licenses and markets innovative advanced technologies and business opportunities created in the Ukraine through a network of scientific institutes and private organizations. CSMG is focused on two primary subsidiaries, Live Tissue Connect, Inc. and landfill gas processing.

For further information on CSMG Technologies and its various subsidiaries, please visit our website at www.csmgtechinternational.com.

Sign up to receive CSMG Technologies automated email press releases and other notifications: Please go to and http://www.csmgtechinternational.com/contact_information.html and fill-in information.

Safe Harbor Statement

This press release may contain forward-looking information within the meaning of Section 21E of the Securities Exchange Act of 1934 as amended (the Exchange Act), including all statements that are not statements of historical fact regarding the intent, belief or current expectations of the company, its directors or its officers with respect to, among other things: (i) the company's financing plans; (ii) trends affecting the company's financial condition or results of operations; (iii) the company's growth strategy and operating strategy; and (iv) the declaration and payment of dividends. The words "may," "would," "will," "expect," "estimate," "anticipate," "believe," "intend" and similar expressions and variations thereof are intended to identify forward-looking statements. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the company's ability to control, and that actual results may differ materially from those projected in the forward-looking statements as a result of various factors.